Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Non-Muscle Invasive Bladder Neoplasms 1

Interventions

pembrolizumab 80Carboplatin 73Paclitaxel 58Cisplatin 58Specimen Handling 56Magnetic Resonance Spectroscopy 56Gemcitabine 48Docetaxel 37Dexamethasone 37Oxaliplatin 34Fluorouracil 33Bevacizumab 33Pemetrexed 32Leucovorin 32Doxorubicin 32Cyclophosphamide 31durvalumab 29Radiotherapy 29Radiation 28Capecitabine 28Rituximab 25Letrozole 25Etoposide 24Nivolumab 23Irinotecan 23Vincristine 22Taxes 21Lenalidomide 21Prednisone 20Bortezomib 20

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × pirarubicin × 30 days × Clear all
NCT07424287 2026-06-02

A Study of Intravesical SHR-1501 Combination With BCG Versus Investigator-selected Chemotherapy in Subjects With BCG-unresponsive NMIBC

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Phase 3 Not yet recruiting
236 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡